Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
East Metropolitan Health Service, Australia
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07651618CT.gov A Phase II Trial of Tumour Infiltrating Lymphocyte Adoptive Cell Therapy in Patients With Immune Checkpoint Inhibitor Resistant Unresectable or Metastatic Melanoma | — | Not Yet Recruiting | — | — | — |
NCT07627698CT.gov Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma | — | Recruiting | — | — | — |
NCT07406724CT.gov HS-IT101 Injection Versus Chemotherapy in the Treatment of Advanced Melanoma | — | Not Yet Recruiting | — | — | — |
NCT07410494CT.gov Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT07287917CT.gov Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT07349303CT.gov Neoadjuvant Pembrolizumab in Patients With Stage IIb/c Melanoma | — | Recruiting | — | — | — |
NCT04119024CT.gov Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT07130032CT.gov Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade | — | Recruiting | — | — | — |
NCT06624644CT.gov A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma | — | Recruiting | — | — | — |
NCT06984328CT.gov Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07) | — | Terminated | — | — | — |
Show 77 more trialsShow fewer
NCT06946225CT.gov ACTengine® IMA203 Combined With mRNA-4203 | — | Recruiting | — | — | — |
NCT07448831CT.gov A Phase II Clinical Trial on Neo-adjuvant Pembrolizumab in Patients With pT3b-T4a/b cN0M0 Melanoma. | — | Recruiting | — | — | — |
NCT06743126CT.gov SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma | — | Recruiting | — | — | — |
NCT06771544CT.gov Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma | — | Recruiting | — | — | — |
NCT06151847CT.gov Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma | — | Completed | — | — | — |
NCT05824975CT.gov A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) | — | Recruiting | — | — | — |
NCT05764395CT.gov Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors | — | Active Not Recruiting | — | — | — |
NCT05492682CT.gov START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer | — | Recruiting | — | — | — |
NCT05576077CT.gov A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT05628883CT.gov Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma | — | Completed | — | — | — |
NCT05544929CT.gov A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | — | Active Not Recruiting | — | — | — |
NCT05341349CT.gov Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases | — | Terminated | — | — | — |
NCT05176470CT.gov Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients | — | Active Not Recruiting | — | — | — |
NCT05269381CT.gov Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT07376317CT.gov Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health System (OTIMAS) | — | Active Not Recruiting | — | — | — |
NCT04697576CT.gov Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma | — | Recruiting | — | — | — |
NCT04708418CT.gov A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma | — | Active Not Recruiting | — | — | — |
NCT05050006CT.gov ITIL-168 in Advanced Melanoma | — | Terminated | — | — | — |
NCT04830124CT.gov Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6 | — | Terminated | — | — | — |
NCT04995094CT.gov Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma | — | Withdrawn | — | — | — |
NCT04902040CT.gov Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies | — | Terminated | — | — | — |
NCT04462406CT.gov Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial | — | Active Not Recruiting | — | — | — |
NCT04301011CT.gov Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors | — | Terminated | — | — | — |
NCT04007744CT.gov Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03842943CT.gov Neoadjuvant Combination Immunotherapy for Stage III Melanoma | — | Recruiting | — | — | — |
NCT03873818CT.gov Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain | — | Completed | — | — | — |
NCT03698019CT.gov A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma | — | Active Not Recruiting | — | — | — |
NCT03589339CT.gov NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy | — | Active Not Recruiting | — | — | — |
NCT03595683CT.gov Pembrolizumab and EDP1503 in Advanced Melanoma | — | Terminated | — | — | — |
NCT03620019CT.gov Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma | — | Completed | — | — | — |
NCT03420963CT.gov Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors | — | Terminated | — | — | — |
NCT03633110CT.gov Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine | — | Completed | — | — | — |
NCT03590054CT.gov Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies | — | Completed | — | — | — |
NCT02965716CT.gov Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma | — | Active Not Recruiting | — | — | — |
NCT03396952CT.gov Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma | — | Completed | — | — | — |
NCT03384836CT.gov Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery | — | Suspended | — | — | — |
NCT03276832CT.gov Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma | — | Completed | — | — | — |
NCT03325101CT.gov Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma | — | Terminated | — | — | — |
NCT03229278CT.gov Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma | — | Completed | — | — | — |
NCT02650986CT.gov Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 | — | Active Not Recruiting | — | — | — |
NCT03050060CT.gov Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer | — | Terminated | — | — | — |
NCT02748564CT.gov Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma | — | Terminated | — | — | — |
NCT03021460CT.gov Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery | — | Active Not Recruiting | — | — | — |
NCT02812693CT.gov Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification | — | Withdrawn | — | — | — |
NCT02858869CT.gov Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases | — | Completed | — | — | — |
NCT02595866CT.gov Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer | — | Completed | — | — | — |
NCT02652455CT.gov Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma | — | Completed | — | — | — |
NCT02650635CT.gov TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors | — | Terminated | — | — | — |
NCT02506153CT.gov Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery | — | Active Not Recruiting | — | — | — |
NCT02500576CT.gov Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT02419495CT.gov Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | — | Terminated | — | — | — |
NCT02298959CT.gov Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer | — | Active Not Recruiting | — | — | — |
NCT01740557CT.gov Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma | — | Completed | — | — | — |
NCT02027935CT.gov CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT01955460CT.gov Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma | — | Active Not Recruiting | — | — | — |
NCT01807182CT.gov Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT01271907CT.gov Drosophila-generated CTL | — | Terminated | — | — | — |
NCT01005537CT.gov Cyclophosphamide, Autologous Lymphocytes, and Aldesleukin in Treating Patients With Metastatic Melanoma | — | No Longer Available | — | — | — |
NCT00704938CT.gov Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer | — | Terminated | — | — | — |
NCT00553683CT.gov Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer | — | Unknown | — | — | — |
NCT00512889CT.gov Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma | — | Completed | — | — | — |
NCT00324623CT.gov Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT00138229CT.gov Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and Interleukin-2 in Treating Patients With Refractory or Recurrent Metastatic Melanoma | — | Terminated | — | — | — |
NCT00118274CT.gov Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma | — | Completed | — | — | — |
NCT00096382CT.gov Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT00091104CT.gov Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT00085462CT.gov Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT00085423CT.gov Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT00079144CT.gov Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT00062036CT.gov Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT00317759CT.gov Fludarabine Followed By Adoptive Immunotherapy in Treating Patients With Stage IV Melanoma | — | Completed | — | — | — |
NCT00045357CT.gov Biological Therapy in Treating Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT00004135CT.gov Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Metastatic Kidney Cancer | — | Completed | — | — | — |
NCT00003715CT.gov Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma | — | Terminated | — | — | — |
NCT00004022CT.gov Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma | — | Completed | — | — | — |
NCT00002535CT.gov Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma | — | Completed | — | — | — |
NCT03311542CT.gov Expanded Access for Pembrolizumab (MK-3475) | — | No Longer Available | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cutaneous Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cyclophosphamide (this asset) | East Metropolitan Health Service, Australia | P3 | BB · 66 |
| Alpha-Interferon | MIPO Clinic | P3 | BBB |
| Dacarbazine | Linnaeus Therapeutics, Inc. | P3 | BBB |
| Tyrosinase Peptide | University of Southern California | P3 | BBB |
| TIL | City of Hope Medical Center | P2 | BBB |
| Cis-Diamminedichloroplatinum Ii | MIPO Clinic | P3 | BBB |
| Multi-Epitope Melanoma Peptide Vaccine | Craig L Slingluff, Jr | P2 | BB |
| Nivestim | Vastra Gotaland Region | P3 | BB |
| Ifa | Craig L Slingluff, Jr | P2 | BB |
+42 more in the Cutaneous Melanoma cohort
Other indications for Cyclophosphamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| Mycosis Fungoides | — | P4 | BBB · 78 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cyclophosphamide in Cutaneous Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cyclophosphamide-cutaneous-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →